The level of chorionic gonadotropin in postmenopausal women with CKD V stage treated with hemodialysis
Abstract
The chorionic gonadotropin (CGT) test is used to diagnose and monitor the course ofpregnancy, including ectopic, to detect fetal abnormalities, trophoblastic diseases, preeclampsia, ovarian tumors, lungs, stomach, intestine, bladder, kidneys, prostate. The level of CGT is often elevated in postmenopausal women treated with hemodialysis (HD). Its significance is still not well understood, and therefore requires further study. The aim of our work was to investigate the level of CGT in postmenopausal women treated with HD.
Methods. The determination of the level of CGT in 23 postmenopausal women treated with HD. The main inclusion criteria were as follows: oral informed consent of the patient to participate in the study, the presence of CKD stage VD and treatment of HD for at least 6 months. Exclusion criteria: severe functional disorders (liver, heart, respiratory failure), cancer processes, smoking, taking substitution hormonal therapy, lack of consent of the patient. The results were compared with the CGT levels in 20 healthy menopausal women (group II).
Results. A statistically significant difference was found between the I group (postmenopausal women treated with HD) and II group (women without chronic kidney disease (CKD) (t = 3.62, p = 0.001). It was also found that CGT was increased in 9 (39%) of 23 women treated with HD. The norm of CGT in postmenopausal women is <14.0 IU/L, therefore the deviation of the index in the I group (13.63 ± 2.83 IU/L) is within the reference values. However, it does not explain the statistically significant difference between the CGT indices in the I group compared to the II group (p<0.01). Possibly, the presence of CKD contributes to the increase in HGT.
Conclusions. Authentically higher rates of CGT in postmenopausal women treated with HD compared with women without CKD were detected. Thus, CKD can affect the serum level of CGT, probably due to disruption, but this issue has not been studied, and requires further investigation.
Downloads
References
Kolesnyk MO, redaktor. Natsionalnyi reiestr kh- vorykh na khronichnu khvorobu nyrok: 2014 rik. Kyiv; 2015. 202 s. [In Ukrainian].
Shanmugavadivoo K, Shaariah W. Health issues in dialysis-dependent female patients. Perit Dial Int. 2003;23(2):192-5.
Hotakainen K., Ljungberg B., Paju A., Rasmuson T., Alfthan H., Stenman U-H. The free β-subunit of human chorionic gonadotropin as a prognostic factor in renal cell carcinoma. Br J Cancer. 2002; 86(2):185-9. doi: 10.1038/sj.bjc.6600050
Palmer B. F. Sexual dysfunction in men and women with chronic kidney disease and end-stage kidney disease. Adv Ren Replace Ther. 2003;10(1):48-60. doi: 10.1053/jarr.2003.50003
Kramer H. M., Curhan G.C., Singh S.A. Hemodialysis and estrogen levels in postmenopaus- al (HELP) patients: The multicenter HELP study. Am J Kidney Dis. 2003;41(6):1240-6. doi: 10.1016/ S0272-6386(03)00357-3
Soni S., Menon M. C., Bhaskaran M., Jhaveri K. D., Molmenti E., Muoio V. Elevated human chorionic gonadotropin levels in patients with chronic kidney disease: Case series and review of literature. Indian J Nephrol. 2013; 23(6): 424–7. doi: 10.4103/0971-4065.120339
Cunningham F.G., Leveno K.J., Bloom S.L. [et al.] Implantation, embryogenesis, and placental devel- opment. 22nd ed. Williams Obstetrics. New York: McGraw-Hill; 2005. p. 39-90.
Mohammed Ilyas M.I., Turner G.D., Cranston D. Human chorionic gonadotropin-secreting clear cell renal cell carcinoma with paraneoplastic gynaeco- mastia. Scand J Urol Nephrol. 2008;42(6):555-7. doi: 10.1080/00365590802468834
Cole L.A., Khanlian S.A., Muller C.Y. Detection of perimenopause or postmenopause human chorion- ic gonadotropin: An unnecessary source of alarm. 2008;198(3):275. doi: 10.1016/j.ajog.2007.09.034
Hayden Y., Bezuidenhout E., de Lange W., O. Van Schalkwyk. Persistent elevation of BHCG-levels in a patient with stage 5D Chronic Kidney Disease. Journal of Endocrinology, Metabolism and Diabetes of South Africa. 2015;20(1):38-46. doi: 10.1080/16089677.2015.1074448
Cao Z.T., Rej R. Are laboratories reporting serum quantitative hCG results correctly? Clin Chem. 2008;54(4):761-4. doi: 10.1373/clinchem.2007.098822
Birken S., Maydelman Y., Gawinowicz M.A., Pound A., Liu Y., Hartree A.S. Isolation and char- acterization of human pituitary chorionic gonado- tropin. Endocrinology. 1996;137(4):1402-11. doi: 10.1210/endo.137.4.8625917